Attention and memory dysfunction is a common complaint among patients with breast cancer that can be reported during and up to several years after treatment. It can negatively affect patients' quality of life and their ability to work. This phenomenon has mainly been studied in patients with breast cancer who are treated with adjuvant chemotherapy. Women describe concentration problems and difficulties with word finding, multitasking, or remembering new information, as well as more effort and time needed to accomplish these tasks. Such cognitive dysfunction is subtle or moderate and occurs in 15% to 25% of patients. Older patients seem more likely to experience cognitive decline with chemotherapy than do young women with breast cancer. Patients who report that cognitive dysfunction has affected their daily lives for 6 to 12 months after the end of chemotherapy or during hormone therapy may need referral to a neuropsychologist. During the cognitive assessment, the etiology of their cognitive complaints is sought and neuropsychological tests are administered to assess objective cognitive functioning. Psychological factors-fatigue and pain-should be assessed systematically with cognitive complaints to identify precisely the cause of the problems. A nonpharmacologic approach-mainly cognitive rehabilitation-seems to be the most promising for the management of these difficulties, but these preliminary results require confirmation. In the future, early detection of cognitive impairment and cognitive rehabilitation should be included in the portfolio of oncology supportive care to facilitate the return to work of young women and to avoid potential repercussions on adherence to oral treatments and on autonomy in older patients.
INTRODUCTION
Complaints of cognitive difficulties reported by patients with breast cancer during and after cancer treatment have led to research on this topic and, little by little, to recognition of the problem by health care professionals. Attention and memory dysfunction is a common complaint among patients with cancer that may be reported during and up to years after treatment. 1 Women describe concentration problems and difficulty in remembering names and numbers, word finding, or multitasking. 2 These disorders can negatively affect quality of life 3, 4 and the ability to work. 5, 6 This phenomenon has been mainly studied in women who have received adjuvant chemotherapy. In addition to these subjective complaints, objective cognitive impairment may also be observed. Postchemotherapy cognitive impairment was found in 15% to 25% of patients with breast cancer. 7 Although these disorders are mild and transient for the majority of patients and abate within 6 to 12 months post-treatment, some patients have persistent impairment even 10 to 20 years after breast cancer chemotherapy. 8, 9 Memory, executive functions, attention, and information processing speed are the main objective domains concerned by cognitive impairment. 10 Structural and functional brain changes have also been evidenced by cerebral imaging, notably in the frontal regions that are involved in executive and memory processes. 10 Whereas this phenomenon was initially termed chemobrain, the presence of cognitive impairment, even before adjuvant treatment [11] [12] [13] [14] and the effect of treatments other than chemotherapy-that is, hormone therapy 15 -has led to the naming of these deficits as cancer-related or chemotherapyrelated cognitive impairment. Indeed, before the start of adjuvant treatment, 20% to 30% of patients with breast cancer already have cognitive deficits as revealed by neuropsychological tests 1 and some anatomic or functional brain imaging anomalies 16, 17 that suggest that cancer itself could induce cognitive disorders. Not only such psychological factors as worry, cancer-related post-traumatic stress, coping style, or fatigue, but also biologic mechanisms, such as tumor-induced neurogenesis, inflammation and/or vascular changes, or comorbidity, could be linked with these pretreatment deficits. [18] [19] [20] [21] [22] [23] Apart from pretreatment impairment, many complex mechanisms are potentially involved in chemotherapy-related cognitive impairment in patients with breast cancer (Fig 1) , such as direct neurotoxic effects caused by chemotherapeutic agents or other cancer treatments or by indirect effects, such as increased cytokine levels and other factors as comorbidity, genetic factors, and aging. 10, 24, 25 However, the exact mechanisms that have been implicated are not well understood and more information is needed to identify subgroups of patients who are at risk. 
Effect of cancer treatment

EFFECT OF COGNITIVE DIFFICULTIES
Consequences in Everyday Life
In addition to being cumulative with other adverse effects of treatment, chemotherapy-related cognitive impairment can negatively affect patients' quality of life, 4, 26, 27 disrupt their return to work, 6 and lead to a decrease in self-confidence at work or in social relationships. 4, [28] [29] [30] In interviews conducted 1 year after breast cancer treatment, survivors reported diminished quality of life and daily functioning as a result of chemotherapy-related cognitive impairment as well as the use of coping strategies to manage their professional and social lives. 4 Some patients also asserted that cognitive impairment is the most troublesome posttreatment symptom. In addition, approximately 6 years after chemotherapy, survivors of breast cancer found that cognitive difficulties were frustrating and detrimental to their self-confidence and social relationships. 30 One half of these women reported having to work harder to perform tasks and using compensatory strategies to perform tasks at work. 30 
Effect on Treatment Adherence
More and more patients with breast cancer receive oral treatments, such as hormone therapy and targeted therapies. Among the many factors that can influence adherence to treatment, cognitive impairment may lead to reduced therapeutic benefit. Indeed, studies have demonstrated a relationship between adherence and prospective memory, executive functioning, working memory, and attention.
30,31
Particularities of Elderly Patients
Although there is wide interindividual heterogeneity, aging by itself is associated with cognitive modifications, comorbidities, and functional decline, which may significantly affect autonomy. Asa resultof the overallincreasein lifeexpectancy that is associated with more appropriate therapeutic care, elderly patients with cancer are expected to live longer and in better conditions. Elderlypatientswithcancer are atparticularrisk for experiencing pretreatment cognitive impairment, which is expected to increase the risk of nonadherence. In addition, older patients are more likely to be affected by different or multiple adverse effects of treatment as a result of their frailty. Chemotherapy-related cognitive impairment is an important adverse effect, and older patients seem to be more likely to experience cognitive decline with chemotherapy than are young women with breast cancer. 32 In older patients, these cognitive impairments could also affect their autonomy in addition to the negative effect on their quality of life. 33 
HOW TO IDENTIFY COGNITIVE DIFFICULTIES
Women report concentration problems, such as during reading a book, and difficulties with word finding, multitasking, or remembering new information, as well as more effort and time needed to accomplish these tasks. 2 Cognitive functioning can be assessed objectively with cognitive tests and subjectively with self-report questionnaires. Cognitive complaints can be assessed by the Functional Assessment of Cancer Therapy-Cognitive Function questionnaire, which was developed from interviews with expert clinicians and oncology patient focus groups. 34, 35 Various studies have reported that 46% to 60% of survivors report persistent cognitive complaints. 36, 37 Whereas cognitive complaints in patients with breast cancer seem to be decreased at 6 months after chemotherapy, which suggests a partial recovery, they do not systematically return to pretreatment levels. 38 Indeed, patients' perceptions of impairment are important because of the significant effect they have on quality of life. Cognitive complaints are not always related to objective cognitive performances, but they correlate strongly with psychological factors. 39 For this reason, anxiety, depression, fatigue, sleep difficulties, and pain should be systematically assessed with cognitive complaints to better identify the origin of the difficulties. The International Cognition and Cancer Task Force recommend using some neuropsychological tests that assess the most objective impaired cognitive domains in patients with cancer. 40 Nevertheless, in clinical practice, particularly with elderly patients, these tests are unable to establish the differential diagnosis between chemotherapy-related cognitive impairment and neurodegenerative disease. Furthermore, sensitive cognitive screening tests, such as the Montreal Cognitive Assessment, may be used if a neuropsychologist is not available in cancer centers. 41 When the results of screening tests
show cognitive frailty, a more detailed cognitive assessment outside of cancer centers could assist in deciding on appropriate therapy, particularly if an adjuvant chemotherapy or oral treatment is planned. 24 Even though it is the best way to reveal cognitive decline, not all patients in routine practice can have a neuropsychological assessment before they begin cancer treatment. Nevertheless, patients who report cognitive dysfunction affecting daily life, persisting 6 to 12 months after the end of chemotherapy, or when they begin hormone therapy, should be referred to a neuropsychologist. 42 Some types of treatment may have more serious adverse effects, and subgroups of patients have already been identified as at-risk populations. Results suggest that regimens that contain anthracyclines could have more negative effects than nonanthracycline-containing regimens, 43 but this remains to be confirmed. Among patients $ 65 years of age, the oldest patients were more likely to experience cognitive decline with chemotherapy, especially when the regimen included docetaxel. 32 Furthermore, older patients with a greater tumor or comorbidity burden may be more susceptible to cognitive impairment. 20 Aging often correlates with frailty, and the toxicity of antitumoral agents is a major concern in elderly patients. For example, in geriatric oncology, a diagnosis of cognitive impairment before treatment may alter clinical decision making.
HOW TO MANAGE COGNITIVE IMPAIRMENT
In 2016, the American Cancer Society-ASCO Breast Cancer Survivorship Care committee published guidelines for the assessment and management of long-term adverse effects, including cognitive impairment. 44 They recommended that primary care clinicians ask patients if they are experiencing cognitive difficulties and assess any factors that may contribute to their cognitive impairment. Furthermore, it was recommended that clinicians treat optimally when possible and refer patients with signs of cognitive impairment for neurocognitive assessment and rehabilitation, including group cognitive training, if available. Nevertheless, as reported by a recent Australian survey of oncologists, clinicians are uncertain about the potential management strategies available. 45 Although there is still no preventive measure available, different methods of managing chemotherapy-related cognitive impairment-therapeutic, physical, behavioral, and cognitive interventions-are being studied and evaluated. Preliminary findings have demonstrated beneficial effects, particularly with nonpharmacologic approaches, but definitive conclusions cannot yet be drawn.
Donepezil, an acetylcholinesterase inhibitor used in the treatment of Alzheimer's disease and vascular dementia, improved only verbal memory performances in survivors of breast cancer who had cognitive complaints several years after chemotherapy. 46 Cognitive rehabilitation seems to be the most promising approach, but additional studies are required to establish its efficacy. Cognitive programs are usually based on the retraining of impaired cognitive abilities, teaching of compensatory strategies, or both. Cognitive rehabilitation meets the expectations of patients with cognitive complaints; in a survey in patients who underwent cancer treatment who had cognitive complaints, 70% would have been interested in participating in cognitive rehabilitation sessions. 26 Overall, cognitive rehabilitation has proven beneficial for cognitive complaints, but less frequently for objective cognitive performances or only on trained cognitive domains. The largest study of cognitive rehabilitation assessed a homebased Web program versus standard care in survivors of cancer (n 5 242) who reported persistent cognitive symptoms 6 to 60 months after adjuvant chemotherapy. An improvement in cognitive complaint and anxiety/depression was found without significant results on cognitive tests. 48 Nevertheless, that study lacked a group with a different type of intervention, which makes it is difficult to draw conclusions about the specific beneficial effect of cognitive rehabilitation-as is the case in many studies with only a waiting list group as control group.
In most cancer centers, cognitive management is not yet included in the portfolio of supportive care. Results of the ongoing studies on different cognitive rehabilitation programs are awaited in order to prove the benefit of these approaches in helping patients live with and after cancer.
years. She had tried to use various coping strategies, such as note taking. She was aware of her difficulties and was concerned about them. Her medical oncologist suggested undergoing neuropsychological tests.
First Neuropsychological Assessment
Mrs C. did not have any medical or psychiatric history or depressive symptoms. Results of the neuropsychological tests corroborated her complaints: slowing of processing speed, word finding, and attentional and short-term memory difficulties. These cognitive complaints justified the proposal of cognitive management. Weekly 2-hour sessions of cognitive rehabilitation were planned for 8 weeks.
Second Neuropsychological Assessment
The follow-up assessment that was carried out after the end of management demonstrated a significant decrease in her cognitive complaints. Her performance in attention, processing speed, and short-term memory were similar to those of the general population, unlike the results of her initial neuropsychological assessment.
In Practice
In clinical practice, a neuropsychological assessment that considers psychological factors should be undertaken before performing cognitive management to identify any cognitive domains that are impaired and to guide cognitive rehabilitation. Figure 2 illustrates the neuropsychological assessment and management of patients who have cognitive difficulties. It is particularly important to assess and manage these cognitive disorders, especially in elderly patients, who are more likely to exhibit age-related cognitive decline before treatment and to experience a cognitive decline with chemotherapy. When an oral treatment is planned for a patient with initial cognitive impairment, follow-up should be reinforced, including home nurse visits or the involvement of caregivers and/or increasing the frequency of medical visits or follow-up with a pharmacist to ensure adherence with medication. For young women, when a return to work is planned, a cognitive assessment could be proposed if they have any cognitive complaints.
In conclusion, cognitive difficulties are reported by some women during and after treatment for breast cancer. Additional research is needed to identify the profile of patients with breast cancer who have a higher risk of cognitive disorders. The promising initial results of cognitive rehabilitation programs should be confirmed with future studies. These programs and the early assessment of cognitive impairment should be included in the portfolio of oncology supportive care to facilitate the return to work of young women and to avoid potential repercussions on adherence to oral treatments and on autonomy in older patients. 
